Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination
Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide
02.06.2024 - Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of ...
Gilt management sets the tone for future productivity of the sow farm. Turn to a trusted vaccine portfolio for the overall health and productivity of your breeding herd.
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase